Beneficial effects of the combination of BCc1 and Hep-S nanochelating-based medicines on IL-6 in hospitalized moderate COVID-19 adult patients: a randomized, double-blind, placebo-controlled clinical trial
Hafizi et al., Trials, doi:10.1186/s13063-023-07624-2
https://c19early.org/hafizi.html